FDA Biologics (BLA & Biosimilars)Original article
Patient Voice in Rare Disease Medical Product Development - 10/16/2026
Neutral
AI Analysis
Summary
The FDA and Reagan-Udall Foundation will convene a hybrid meeting on October 16, 2026 to discuss the role of patient voice in rare disease medical product development across biologics, drugs, and devices.
Importance:2/10
Sentiment:
0.00
Rare DiseasePatient EngagementRegulatory MeetingMedical Product Development
Related Companies
Read the original article
Published by FDA Biologics (BLA & Biosimilars) on September 9, 2026 3:25 PM